Percentage of participants with adverse effects and severe adverse effects · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · delirious patients
It is very uncertain whether antipsychotics changes adverse Effects ‐ EPS Extrapyramidal Symptom Rating Scale, or not… compared with nonantipsychotics or placebo (very low certainty).
1 finding from 1 review
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with both severe mental illness and substance misuse
1 finding from 1 review
Intervention not reported
Any adverse side effects (total), as defined and reported by trial authors · menstruating women (non‐pregnant women of reproductive age)
The intervention showed no clear difference in any adverse side effects (total), as defined and reported by trial… (low certainty).
1 finding from 1 review
Proportion of patients with adverse effects№ of participants: 819(12 RCTs) · patients with symptoms of vertigo
Betahistine showed no clear difference in proportion of patients with adverse effects№ of participants: 819(12… compared with placebo (low certainty).
1 finding from 1 review
Side effects / adverse effects (unilateral crossbite; transverse problems) · Children and adolescents (over 80% aged 16 years or younger at treatment start) with anterior open bite (lack of vertical overlap or…
1 finding from 1 review
Orthodontic and orthopaedic treatment for anterior open bite in children 2014 · Cochrane All outcomesAbout 4 months (treatment interrupted early)
"After 4 months the open bite was observed to close in the magnet group, but in four out of these ten patients, transverse problems were observed (unilateral crossbite) which led to the interruption of the treatment…
1 study · 10 participants
GRADE not reported
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia
QUETIAPINE probably leads to lower adverse effects: 2. Extrapyramidal effects use of antiparkinson… compared with PALIPERIDONE (moderate certainty).
1 finding from 1 review
Post-operative adverse events and complications · Patients with chronic periodontitis (aged 21 years or older) with periodontal infra-bony defects; furcation-involved teeth and aggressive…
1 finding from 1 review
Other adverse effects (gastrointestinal upset, headache, allergic reaction) · adults with tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Adverse effects ‐ burns, skin damage, or cardiac arrhythmias ‐ not measured · for quadriceps strengthening pre and post total knee replacement
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in incidence of any adverse effects after treatment initiation (up to 3… compared with prednisolone (low certainty).
1 finding from 1 review
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found